Metabolic Research Peptides

Why "Metabolic Research" Is a Category

The metabolic-research peptide family is unified by a shared signalling biology: the incretin axis. The two native incretins - glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) - are released from intestinal enteroendocrine cells in response to nutrient intake and amplify glucose-dependent insulin secretion from pancreatic β-cells. Glucagon, released from α-cells, is the counter-regulatory hormone. Amylin, co-secreted with insulin from β-cells, modulates gastric emptying and satiety pathways.

Synthetic peptide analogues at these four receptor systems - GLP-1R, GIPR, glucagon receptor (GCGR), and amylin receptor (AMY) - have driven a decade of metabolic-research literature. The compounds in this category span the full spectrum: single-target agonists (Semaglutide, Liraglutide, Dulaglutide), dual agonists (Tirzepatide, Mazdutide), triple agonists (Retatrutide), and amylin analogues (Cagrilintide).

The Seven Compounds at a Glance

Compound	Receptor profile	Half-life (literature)	Sizes
Tirzepatide	Dual GIP / GLP-1 agonist	~120 hours	2–120 mg
Retatrutide	Triple GLP-1 / GIP / glucagon agonist	~6 days	5–60 mg
Semaglutide	Single GLP-1 agonist	~165 hours	2–30 mg
Liraglutide	Single GLP-1 agonist (97% homology)	~13 hours	5–30 mg
Mazdutide	Dual GLP-1 / glucagon agonist	~5 days	5–10 mg
Cagrilintide	Long-acting amylin analogue	~159 hours	2–10 mg
Dulaglutide	GLP-1 Fc-fusion (single-target)	~5 days	5–10 mg

Single-target GLP-1 Receptor Agonists

The single-target class is the most thoroughly characterised in published metabolic research. Three compounds in our catalogue fit this description:

• Semaglutide - 31-amino-acid peptide with ~94% sequence homology to native GLP-1. Lys-26 fatty-acid acylation extends half-life to ~165 hours, supporting once-weekly dosing in published research. Approved by FDA in 2017 and the most widely cited GLP-1 reference standard in current literature.
• Liraglutide - 31-amino-acid analogue with ~97% homology to native GLP-1, modified with a γGlu-C16 fatty-acid linker. Half-life of ~13 hours supports once-daily dosing in published research models.
• Dulaglutide - GLP-1 dimer fused to a modified IgG4 Fc fragment. The Fc-fusion architecture extends half-life to ~5 days through FcRn recycling.

Dual and Triple Receptor Agonists

The next generation of metabolic-research peptides combines GLP-1 receptor activity with GIP and/or glucagon receptor agonism. Two of the four compounds in this class are in our catalogue:

• Tirzepatide - the first dual GIP/GLP-1 agonist to reach late-stage research literature. 39-amino-acid peptide with α-aminoisobutyric acid substitutions for enzymatic stability and Lys-20 fatty-acid acylation for albumin binding. Reported half-life ~120 hours. Approved by FDA in 2022.
• Retatrutide - the first triple GLP-1/GIP/glucagon agonist to reach Phase 3. 39-amino-acid peptide with reported half-life ~6 days. Phase 2 data published in NEJM (2023) showed the largest weight-loss outcomes in incretin-class research to date. Currently the most novel compound in the metabolic-research peptide family.
• Mazdutide - oxyntomodulin-class dual GLP-1/glucagon agonist (LY3305677/IBI362). Phase 3 trials reported in 2023–2026 literature. The 39-residue peptide combines GLP-1 satiety signalling with glucagon-driven energy expenditure.

Amylin Analogue

Amylin is co-secreted with insulin from pancreatic β-cells and acts through the amylin (AMY) receptor family - calcitonin receptor heterodimers with RAMP1/2/3 modulators. Native amylin has poor solubility and aggregation issues that synthetic analogues address.

• Cagrilintide - 32-amino-acid long-acting amylin analogue with C18 fatty-acid acylation. Reported half-life ~159 hours. Frequently studied in combination with Semaglutide (CagriSema combination) in published research literature.

Compare Compounds Side by Side

Researchers often choose between two specific compounds within this category. Direct comparison pages:

• Tirzepatide vs Retatrutide - dual vs triple receptor agonist.
• Tirzepatide vs Semaglutide - dual GIP/GLP-1 vs single GLP-1 agonist.
• Semaglutide vs Retatrutide - single vs triple receptor agonist.
• Semaglutide vs Liraglutide - once-weekly vs once-daily GLP-1 agonist.

Selection Criteria for Metabolic Research

Choose a compound based on the experimental hypothesis being tested. Key questions:

Single vs multi-receptor research

If the experimental question is GLP-1-receptor-isolated (e.g., GLP-1R signalling kinetics, β-cell-specific effects, or comparator studies against published GLP-1R literature), Semaglutide or Liraglutide is the cleanest reference. If the question concerns combined receptor signalling or polypharmacology, choose Tirzepatide (dual) or Retatrutide (triple).

Half-life and dosing pattern

Short half-life compounds (Liraglutide, ~13 hours) suit research models requiring more frequent dosing or that mimic native pulsatile signalling. Long half-life compounds (Semaglutide, Tirzepatide, Retatrutide) suit once-weekly research dosing.

Adipose-tissue or hepatic research

Glucagon-receptor agonism (Mazdutide, Retatrutide) is associated in published literature with energy-expenditure and hepatic-lipid effects. Choose accordingly if the hypothesis is hepatic or adipose research.

Combination research

Cagrilintide + Semaglutide (CagriSema) is the canonical published combination protocol in this category. Both compounds are in our catalogue.

Laboratory Handling - General Notes

All metabolic-research peptides in this category are supplied as lyophilised (freeze-dried) powder in sealed glass vials. For laboratory reconstitution:

1. Equilibrate the vial to room temperature before opening.
2. Add the desired volume of bacteriostatic water slowly down the side wall - do not pipette directly onto the lyophilised cake.
3. Swirl gently until fully dissolved. Do not vortex or shake.
4. Store reconstituted solutions at 2–8 °C; use within 28 days for most compounds (some shorter - see compound page).
5. Use the on-site Reconstitution Volume Calculator to compute resulting mg/mL.

Purity & Verification

Compounds in this category are independently HPLC-verified by Janoshik Analytical at 99%+ purity. Where a Janoshik report has been issued for the current batch it is supplied with the order, and verification records are published on the Purity page so you can match the printed report to the public record.

Browse Related Categories

• GHRH / Secretagogue Research - sermorelin, CJC 1295, ipamorelin, tesamorelin, GHRP-2, GHRP-6, IGF-1 LR3, HGH.
• Regenerative Research - BPC-157, TB-500, GHK-Cu, thymosin α1, ipamorelin.
• Neuropeptide Research - semax, selank, DSIP, melatonin, oxytocin, kisspeptin-10, PT-141.
• Full Catalogue (44 compounds)

Order & Enquiries

Click any compound above to view current stock, sizes, prices and order via WhatsApp or email. Bulk orders, multi-compound research bundles, and academic procurement are accommodated - visit the Wholesale page or contact us directly.